TWI561529B - Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type - Google Patents

Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type

Info

Publication number
TWI561529B
TWI561529B TW103109373A TW103109373A TWI561529B TW I561529 B TWI561529 B TW I561529B TW 103109373 A TW103109373 A TW 103109373A TW 103109373 A TW103109373 A TW 103109373A TW I561529 B TWI561529 B TW I561529B
Authority
TW
Taiwan
Prior art keywords
immunotherapy
dementia
alzheimer
prevention
type
Prior art date
Application number
TW103109373A
Other languages
English (en)
Chinese (zh)
Other versions
TW201434478A (zh
Inventor
Chang Yi Wang
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Publication of TW201434478A publication Critical patent/TW201434478A/zh
Application granted granted Critical
Publication of TWI561529B publication Critical patent/TWI561529B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW103109373A 2013-03-15 2014-03-14 Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type TWI561529B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/843,883 US9102752B2 (en) 2013-03-15 2013-03-15 Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type

Publications (2)

Publication Number Publication Date
TW201434478A TW201434478A (zh) 2014-09-16
TWI561529B true TWI561529B (en) 2016-12-11

Family

ID=51527985

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103109373A TWI561529B (en) 2013-03-15 2014-03-14 Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type

Country Status (18)

Country Link
US (4) US9102752B2 (enExample)
EP (1) EP2968485B1 (enExample)
JP (3) JP6208319B2 (enExample)
KR (2) KR101926030B1 (enExample)
CN (2) CN108794615A (enExample)
AU (3) AU2013381835A1 (enExample)
BR (1) BR112015023105A8 (enExample)
CA (1) CA2906313A1 (enExample)
DK (1) DK2968485T3 (enExample)
ES (1) ES2800028T3 (enExample)
IL (2) IL241597B (enExample)
MX (2) MX364689B (enExample)
PT (1) PT2968485T (enExample)
RU (1) RU2696566C2 (enExample)
SG (1) SG11201507669YA (enExample)
TW (1) TWI561529B (enExample)
WO (1) WO2014143087A1 (enExample)
ZA (2) ZA201507526B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
AU2015243990A1 (en) * 2014-04-07 2016-11-10 La Jolla Pharmaceutical Company Hepcidin mimetic peptides and uses thereof
EP3409130B1 (en) 2016-01-27 2020-11-25 Industry-Academic Cooperation Foundation Gyeongsang National University Composition for preventing, alleviating or treating neurological disorders, containing, as active ingredient, novel peptide activating adiponectin receptors
WO2017179646A1 (ja) * 2016-04-14 2017-10-19 Ｔａｏヘルスライフファーマ株式会社 アミロスフェロイド（ａｓｐｄ）様構造体及び医薬組成物
CN106565847B (zh) * 2016-10-26 2020-12-01 清华大学 化合物、多肽及其用途
US20210138049A1 (en) * 2017-06-16 2021-05-13 United Neuroscience Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies
AU2018355574B2 (en) * 2017-10-27 2025-09-04 United Neuroscience Tau peptide immunogen constructs
KR102745247B1 (ko) * 2017-12-11 2024-12-23 유비아이 아이피 홀딩스 아토피성 피부염의 치료 및/또는 예방을 위한 il-31의 펩타이드 면역원 및 이의 제형물
WO2019133024A1 (en) * 2017-12-31 2019-07-04 United Biomedical, Inc. Peptide immunogens and formulations thereof targeting membrane-bound ige for treatment of ige mediated allergic diseases
CA3091020A1 (en) * 2018-02-13 2019-08-22 Cedars-Sinai Medical Center Methods and systems for identification and treatment of pathological neurodegeneration and age-related cognitive decline
PE20201344A1 (es) 2018-04-10 2020-11-25 Ac Immune Sa Vacunas terapeuticas anti-abeta
WO2019213555A1 (en) * 2018-05-04 2019-11-07 Ubi Us Holdings, Llc Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response
TWI676635B (zh) * 2018-06-15 2019-11-11 英屬開曼群島商聯腦科學公司 α－突觸核蛋白Ｃ端胜肽免疫原及其用於治療突觸核蛋白疾病的配方
US20210347866A1 (en) * 2018-10-01 2021-11-11 United Neuroscience Peptide immunogen constructs directed against dipeptide repeat proteins from c9orf72
WO2020132275A1 (en) * 2018-12-19 2020-06-25 Ubi Ip Holdings Artificial promiscuous t helper cell epitopes as immune stimulators for synthetic peptide immunogens
BR112021012668A2 (pt) * 2018-12-28 2021-12-28 United Biomedical Inc Imunógenos de peptídeos que possuem como alvo interleucina 6 (il-6) e formulações dos mesmos para imunoterapia de doenças impactadas pela desregulação de il-6
BR112021012906A2 (pt) * 2018-12-31 2021-12-28 United Neuroscience Ltd Imunógenos de peptídeo que têm como alvo peptídeo relacionado ao gene da calcitonina (cgrp) e formulações dos mesmos para prevenção e tratamento de enxaqueca
CN110759987B (zh) * 2019-10-29 2021-06-08 中国人民解放军军事科学院军事医学研究院 构象特异性的重组Aβ1-42样寡聚体抗原、其制备方法和应用
BR112022014616A2 (pt) * 2020-01-23 2022-12-13 United Biomedical Inc Imunógenos peptídicos de alvejamento de peptídeo ativador de adenilato ciclase pituitária (pacap) e formulações do mesmo para prevenção e tratamento de enxaqueca
US20230151069A1 (en) 2020-03-10 2023-05-18 Lifearc Cyclic Peptides
AU2021385036A1 (en) 2020-11-17 2023-06-08 ILiAD Biotechnologies, Inc. Treatment and prevention of neuropathology associated with neurodegenerative diseases
US20240159777A1 (en) * 2021-03-16 2024-05-16 Neurovision Imaging, Inc. Biofluid-Based Methods for Diagnosing Alzheimer’s Disease-Associated Conditions
US20240241122A1 (en) * 2021-05-20 2024-07-18 Denka Company Limited Anti-norovirus antibody
JP2024534269A (ja) * 2021-08-30 2024-09-18 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 神経変性疾患を治療するための方法および物質
US20250057928A1 (en) 2021-12-08 2025-02-20 Osaka University Vaccine composition for inducing anti-il-23 antibody
US20250186580A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
CN117586370A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体及其用途
KR102530956B1 (ko) * 2022-09-08 2023-05-11 주식회사 알츠코리아 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도
CN115417915B (zh) * 2022-11-03 2023-02-24 北京引正基因科技有限公司 多肽载体及其应用
CN117122612B (zh) * 2023-07-07 2024-08-27 河络新图生物科技(上海)有限公司 外周血单个核细胞在制备治疗/预防阿尔茨海默病的药物中的用途
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951909B2 (en) * 2001-05-25 2011-05-31 United Biomedical, Inc. Immunogenic peptide composition comprising a promiscuous helper T cell epitope and an N-terminal fragment of Aβ1-42 peptide
US20110171243A1 (en) * 2008-06-12 2011-07-14 Affiris Ag Compounds for treating amyloidoses

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
JP2980677B2 (ja) 1990-04-27 1999-11-22 マクマイケル，ジョン 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
EP0683234B2 (en) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
AU7043894A (en) 1993-05-28 1994-12-20 Miriam Hospital, The Composition and method for (in vivo) imaging of amyloid deposits
WO1995011998A1 (en) 1993-10-26 1995-05-04 United Biomedical, Inc. Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6025468A (en) 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
ES2344189T3 (es) 1999-09-03 2010-08-20 RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. Agentes, composiciones y metodos que los utilizan utiles en el tratamiento o la prevencion de la enfermedad de alzheimer.
CN101935352A (zh) 1999-12-08 2011-01-05 智力神经系统学公司 作为免疫原的嵌合肽及其抗体,以及利用嵌合肽或抗体进行免疫的方法
US20030165481A1 (en) 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
US20030083277A1 (en) * 2000-02-24 2003-05-01 Hersh Louis B. Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
EP1523499A2 (en) * 2002-07-24 2005-04-20 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
JP2007522119A (ja) * 2004-01-28 2007-08-09 キュリックス エーピーエス アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート
US8034353B2 (en) * 2006-02-22 2011-10-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Peptide vaccine for inducing the production of anti-amyloid β-peptide antibody
EP1996227A2 (en) * 2006-02-24 2008-12-03 CHIESI FARMACEUTICI S.p.A. Anti-amyloid immunogenic compositions, methods and uses
WO2008021296A2 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of alzheimer's disease
EP2342356A4 (en) * 2008-09-29 2012-11-21 Univ Ben Gurion AMYLOID BETA PEPTIDASES AND METHOD OF USE THEREOF
US9067981B1 (en) * 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8916387B2 (en) * 2010-10-28 2014-12-23 Jonas Nilsson Diagnosis and treatment of Alzheimer's disease
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951909B2 (en) * 2001-05-25 2011-05-31 United Biomedical, Inc. Immunogenic peptide composition comprising a promiscuous helper T cell epitope and an N-terminal fragment of Aβ1-42 peptide
US20110171243A1 (en) * 2008-06-12 2011-07-14 Affiris Ag Compounds for treating amyloidoses

Also Published As

Publication number Publication date
US20140271690A1 (en) 2014-09-18
CN105228644A (zh) 2016-01-06
ZA201507526B (en) 2019-12-18
JP2017226646A (ja) 2017-12-28
ES2800028T3 (es) 2020-12-23
US9102752B2 (en) 2015-08-11
US20190194280A1 (en) 2019-06-27
KR101926030B1 (ko) 2018-12-10
IL265910A (en) 2019-06-30
SG11201507669YA (en) 2015-10-29
AU2019246916A1 (en) 2019-10-31
IL241597B (en) 2020-07-30
KR20180132962A (ko) 2018-12-12
ZA201906683B (en) 2023-04-26
MX2015013235A (es) 2016-04-04
CN105228644B (zh) 2018-07-13
KR20150132396A (ko) 2015-11-25
JP6208319B2 (ja) 2017-10-04
EP2968485A1 (en) 2016-01-20
US20160068581A1 (en) 2016-03-10
US20180244739A1 (en) 2018-08-30
BR112015023105A2 (pt) 2017-11-21
RU2019123453A (ru) 2019-09-10
EP2968485B1 (en) 2020-03-04
AU2017203425B2 (en) 2019-07-11
RU2015142996A (ru) 2017-04-24
JP2016513638A (ja) 2016-05-16
TW201434478A (zh) 2014-09-16
AU2013381835A1 (en) 2015-10-08
JP2019196397A (ja) 2019-11-14
MX2019005268A (es) 2019-07-01
AU2017203425A1 (en) 2017-06-08
HK1212600A1 (zh) 2016-06-17
DK2968485T3 (da) 2020-06-08
MX364689B (es) 2019-05-06
EP2968485A4 (en) 2016-09-07
CN108794615A (zh) 2018-11-13
WO2014143087A1 (en) 2014-09-18
BR112015023105A8 (pt) 2018-01-23
JP6784646B2 (ja) 2020-11-11
CA2906313A1 (en) 2014-09-18
RU2696566C2 (ru) 2019-08-05
PT2968485T (pt) 2020-06-26

Similar Documents

Publication Publication Date Title
ZA201906683B (en) Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type
IL256296A (en) Particles of dimethyl fumarate and pharmaceutical preparations thereof
HUE052074T2 (hu) Mutáns VIII-as faktor készítmények és módszerek
IL265269B (en) New compounds and their medicinal uses
SI3231793T1 (sl) Spojine dihidropirimidin-2-ona in njihove medicinske uporabe
IL248711A (en) Epixaben glycol esters as major intermediates and impurities in the process of epixaben synthesis
EP3199543A4 (en) Novel peptide and use thereof
IL287985A (en) A peptide derived from koc1 and a component containing it
IL257335A (en) A depdc1-derived peptide and a component containing it
GB201423272D0 (en) The combination for anti-wrinkle and soothing the skin
IL258700A (en) An excipient and a vaccine that includes it
IL250235A0 (en) A peptide derived from urlc10 and a component containing it
IL251289B (en) New peptide derivatives and their use
EP3102590A4 (en) Antigenic epitopes from ebv gp350/220 and uses thereof
HUE047778T2 (hu) Dezmoglein 3 peptidek Pemphigus vulgarisban
IL250215A0 (en) A peptide derived from cdca1 and a component containing it
IL251135A0 (en) A method for the synthesis of hydroxy-triglycerides and their use for the prevention and treatment of diseases
LT3226827T (lt) Aliuminio neturinčio antiperspiranto (dezodoranto) kompozicijos ir jų gavimo būdai
GB201421888D0 (en) Peptides derived from mysoin 19 and methods of use thereof
GB201615560D0 (en) Novel compounds and therapeutic uses thereof
GB201417777D0 (en) Novel compounds and therapeutic uses thereof
GB201402040D0 (en) Tie 'Not
GB201414038D0 (en) Alzheimer's disease